{"id":"humira-sc","safety":{"commonSideEffects":[{"rate":"12-20","effect":"Injection site reactions"},{"rate":"7-10","effect":"Upper respiratory tract infections"},{"rate":"5-8","effect":"Headache"},{"rate":"0.1-0.5","effect":"Tuberculosis reactivation"},{"rate":"2-4","effect":"Serious infections"}]},"_chembl":{"chemblId":"CHEMBL1397913","moleculeType":"Small molecule","molecularWeight":"339.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab blocks TNF-α, a key pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. By neutralizing TNF-α, it suppresses the inflammatory cascade and reduces immune-mediated tissue damage. The subcutaneous formulation allows for patient self-administration and improved convenience compared to intravenous routes.","oneSentence":"Humira SC is a subcutaneous formulation of adalimumab, a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:26.397Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"},{"name":"Hidradenitis suppurativa"}]},"trialDetails":[{"nctId":"NCT04527380","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-04-13","conditions":"Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis","enrollment":101},{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT06100744","phase":"PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-08","conditions":"Juvenile Psoriatic Arthritis","enrollment":40},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT03651518","phase":"PHASE2","title":"Personalized Therapies in Inflammatory Complex Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-20","conditions":"Inflammatory Disease, Autoimmune Diseases","enrollment":32},{"nctId":"NCT06257875","phase":"PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-03-23","conditions":"Ulcerative Colitis","enrollment":156},{"nctId":"NCT07151937","phase":"PHASE2","title":"A Study of LAD191 in Adults With Hidradenitis Suppurativa","status":"NOT_YET_RECRUITING","sponsor":"Almirall, S.A.","startDate":"2025-09","conditions":"Hidradenitis Suppurativa","enrollment":200},{"nctId":"NCT03316781","phase":"PHASE3","title":"Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-10-27","conditions":"Plaque Psoriasis","enrollment":262},{"nctId":"NCT04985435","phase":"PHASE4","title":"Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)","status":"RECRUITING","sponsor":"R.Bos","startDate":"2021-05-12","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT03915964","phase":"PHASE4","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-25","conditions":"Rheumatoid Arthritis","enrollment":2663},{"nctId":"NCT04086745","phase":"PHASE4","title":"A Study of Baricitinib in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-14","conditions":"Rheumatoid Arthritis","enrollment":1317},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT05414201","phase":"PHASE4","title":"A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-07-07","conditions":"Non-infectious Intermediate Posterior- or Pan-uveitis","enrollment":87},{"nctId":"NCT05108259","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects","status":"RECRUITING","sponsor":"Prestige Biopharma Limited","startDate":"2022-03-30","conditions":"Healthy Volunteers","enrollment":324},{"nctId":"NCT05040464","phase":"PHASE3","title":"Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-08-26","conditions":"Crohn Disease, Azathioprine, Methotrexate","enrollment":166},{"nctId":"NCT03261102","phase":"NA","title":"TDM Guided Early Optimization of ADAL in Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"waqqas.afif","startDate":"2017-01-17","conditions":"Crohn Disease, Drug Monitoring, Inflammatory Bowel Diseases","enrollment":200},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":"Crohn Disease","enrollment":386},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT04088409","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-10-16","conditions":"Uveitis","enrollment":30},{"nctId":"NCT05884242","phase":"PHASE1","title":"A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-05-22","conditions":"Healthy","enrollment":20},{"nctId":"NCT04909801","phase":"PHASE3","title":"A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-09-15","conditions":"Rheumatoid Arthritis","enrollment":338},{"nctId":"NCT02852694","phase":"PHASE4","title":"Reduce Risk for Crohn's Disease Patients","status":"COMPLETED","sponsor":"PIBD-Net","startDate":"2017-02-28","conditions":"Crohn's Disease","enrollment":192},{"nctId":"NCT05169593","phase":"PHASE4","title":"Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-09-08","conditions":"Crohn Disease","enrollment":292},{"nctId":"NCT06242652","phase":"PHASE2","title":"A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-03-19","conditions":"Ankylosing Spondylitis","enrollment":250},{"nctId":"NCT05637515","phase":"PHASE3","title":"Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity","status":"COMPLETED","sponsor":"Biocon Biologics Inc.","startDate":"2022-11-21","conditions":"Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis","enrollment":374},{"nctId":"NCT04230213","phase":"PHASE3","title":"A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-01-13","conditions":"Rheumatoid Arthritis","enrollment":455},{"nctId":"NCT05073315","phase":"PHASE3","title":"A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-10-04","conditions":"Plaque Psoriasis","enrollment":425},{"nctId":"NCT04988308","phase":"PHASE2","title":"A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-12","conditions":"Hidradenitis Suppurativa","enrollment":151},{"nctId":"NCT02760407","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-06-06","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT05995691","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-11-24","conditions":"Healthy Volunteers","enrollment":179},{"nctId":"NCT02764762","phase":"PHASE4","title":"Triple Combination Therapy in High Risk Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-18","conditions":"Crohn Disease","enrollment":55},{"nctId":"NCT05909852","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-07-23","conditions":"Adalimumab","enrollment":372},{"nctId":"NCT05510063","phase":"PHASE4","title":"Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2022-08-04","conditions":"Plaque Psoriasis","enrollment":371},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":"Arthritis, Rheumatoid","enrollment":159},{"nctId":"NCT03172377","phase":"PHASE4","title":"Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2017-05-03","conditions":"Crohn Disease in Remission, Crohn Disease","enrollment":174},{"nctId":"NCT04551352","phase":"PHASE1","title":"A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-10-28","conditions":"Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma","enrollment":20},{"nctId":"NCT04224194","phase":"PHASE3","title":"Auto-injector Real Life Handling in Patients","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-11-04","conditions":"RA","enrollment":107},{"nctId":"NCT04453137","phase":"PHASE3","title":"Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2020-06-30","conditions":"Plaque Psoriasis","enrollment":567},{"nctId":"NCT02332590","phase":"PHASE3","title":"Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01-28","conditions":"Rheumatoid Arthritis","enrollment":369},{"nctId":"NCT02714322","phase":"PHASE3","title":"MYL-1401A Efficacy and Safety Comparability Study to Humira®","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-06","conditions":"Psoriasis, Arthritis, Psoriatic","enrollment":294},{"nctId":"NCT04705844","phase":"PHASE3","title":"Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)","status":"WITHDRAWN","sponsor":"Alachua Government Services, Inc.","startDate":"2021-09","conditions":"Mild to Moderate COVID-19","enrollment":""},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT05153200","phase":"PHASE4","title":"Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-01","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT03970824","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-05-31","conditions":"Healthy","enrollment":312},{"nctId":"NCT04171414","phase":"PHASE3","title":"A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-09-09","conditions":"Rheumatoid Arthritis","enrollment":62},{"nctId":"NCT03789292","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2018-11-26","conditions":"Rheumatoid Arthritis","enrollment":648},{"nctId":"NCT02471118","phase":"PHASE2","title":"Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)","status":"COMPLETED","sponsor":"CARE ARTHRITIS LTD.","startDate":"2015-03","conditions":"Osteoarthritis, Knee","enrollment":62},{"nctId":"NCT03607903","phase":"PHASE1, PHASE2","title":"Adalimumab Microneedles in Healthy Volunteers","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-07-11","conditions":"Pain, Injection Site","enrollment":24},{"nctId":"NCT02694523","phase":"PHASE3","title":"BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":684},{"nctId":"NCT02171429","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-11-14","conditions":"Ulcerative Colitis","enrollment":358},{"nctId":"NCT02163759","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-11-04","conditions":"Ulcerative Colitis","enrollment":358},{"nctId":"NCT03823391","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-03-27","conditions":"Rheumatoid Arthritis (RA)","enrollment":48},{"nctId":"NCT01148225","phase":"PHASE3","title":"A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2010-11-23","conditions":"Uveitis","enrollment":424},{"nctId":"NCT01064856","phase":"PHASE3","title":"Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-02","conditions":"Peripheral Spondyloarthritis","enrollment":165},{"nctId":"NCT04643483","phase":"PHASE3","title":"A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease","status":"WITHDRAWN","sponsor":"UCB Biopharma SRL","startDate":"2021-06","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT01764321","phase":"","title":"Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":1723},{"nctId":"NCT03151551","phase":"PHASE4","title":"A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-08-24","conditions":"Psoriatic Arthritis","enrollment":566},{"nctId":"NCT01197144","phase":"NA","title":"Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2010-10","conditions":"Arthritis, Rheumatoid, Pain, Fatigue","enrollment":70},{"nctId":"NCT02065557","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-13","conditions":"Ulcerative Colitis","enrollment":101},{"nctId":"NCT03849404","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-02-20","conditions":"Plaque Psoriasis","enrollment":413},{"nctId":"NCT02808975","phase":"PHASE4","title":"Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-18","conditions":"Hidradenitis Suppurativa (HS)","enrollment":206},{"nctId":"NCT02497469","phase":"PHASE3","title":"An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-06-29","conditions":"Colitis, Ulcerative","enrollment":771},{"nctId":"NCT02696785","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-05-02","conditions":"Spondyloarthritis","enrollment":341},{"nctId":"NCT02750800","phase":"","title":"Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-07","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":427},{"nctId":"NCT01710358","phase":"PHASE3","title":"A Study in Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":1307},{"nctId":"NCT02668640","phase":"","title":"Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-05-01","conditions":"Rheumatoid Arthritis","enrollment":55},{"nctId":"NCT01736189","phase":"","title":"Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-10-11","conditions":"Rheumatoid Arthritis","enrollment":346},{"nctId":"NCT02393378","phase":"PHASE2","title":"Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate","status":"TERMINATED","sponsor":"Takeda","startDate":"2015-04-08","conditions":"Rheumatoid Arthritis","enrollment":7},{"nctId":"NCT02480153","phase":"PHASE3","title":"A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-06-25","conditions":"Rheumatoid Arthritis","enrollment":597},{"nctId":"NCT02333383","phase":"","title":"Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-12-31","conditions":"Ankylosing Spondylitis","enrollment":201},{"nctId":"NCT02533375","phase":"PHASE3","title":"Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-09-28","conditions":"Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese","enrollment":10},{"nctId":"NCT01695239","phase":"PHASE3","title":"A Study of Ixekizumab in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-12","conditions":"Psoriasis, Arthritic","enrollment":417},{"nctId":"NCT01029847","phase":"PHASE4","title":"Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2009-12","conditions":"Spondyloarthritis","enrollment":49},{"nctId":"NCT03580876","phase":"PHASE4","title":"Addition of Azathioprine in IBD Patients With Immunogenic Failure","status":"UNKNOWN","sponsor":"Védrines, Philippe, M.D.","startDate":"2018-07-23","conditions":"Clinical Failure After Switch","enrollment":90},{"nctId":"NCT02722044","phase":"PHASE3","title":"Usability of an AI for M923 in Subjects With Moderate to Severe RA","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2016-04","conditions":"Rheumatoid Arthritis","enrollment":33},{"nctId":"NCT01543204","phase":"PHASE4","title":"Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab","status":"TERMINATED","sponsor":"Amgen","startDate":"2012-02-01","conditions":"Psoriasis","enrollment":64},{"nctId":"NCT00650156","phase":"PHASE1","title":"Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2007-06","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT02019472","phase":"PHASE3","title":"A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-04-04","conditions":"Arthritis, Rheumatoid","enrollment":559},{"nctId":"NCT01483599","phase":"PHASE2","title":"A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2011-11-10","conditions":"Psoriasis","enrollment":293},{"nctId":"NCT02016482","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01","conditions":"Nail Psoriasis, Plaque Psoriasis","enrollment":217},{"nctId":"NCT01674413","phase":"PHASE3","title":"Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)","status":"WITHDRAWN","sponsor":"Peter Higgins","startDate":"2013-10","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02114931","phase":"PHASE3","title":"Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-04","conditions":"Arthritis, Rheumatoid","enrollment":467},{"nctId":"NCT01083680","phase":"","title":"Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2007-05","conditions":"Crohn's Disease","enrollment":4107},{"nctId":"NCT00480272","phase":"PHASE4","title":"Prospective Study on Intensive Early Rheumatoid Arthritis Treatment","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2007-05","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT00814255","phase":"PHASE2","title":"Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2008-12","conditions":"Focal Segmental Glomerulosclerosis","enrollment":32},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT01029613","phase":"","title":"Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers","status":"COMPLETED","sponsor":"Glostrup University Hospital, Copenhagen","startDate":"2009-12","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT01870284","phase":"PHASE3","title":"Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)","status":"WITHDRAWN","sponsor":"Eli Lilly and Company","startDate":"2014-07","conditions":"Spondylitis, Ankylosing","enrollment":""},{"nctId":"NCT01283971","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":96},{"nctId":"NCT01185301","phase":"PHASE3","title":"Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-10","conditions":"Early Rheumatoid Arthritis","enrollment":395},{"nctId":"NCT01265823","phase":"PHASE4","title":"Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-10","conditions":"Psoriasis","enrollment":150},{"nctId":"NCT00853385","phase":"PHASE3","title":"A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-05","conditions":"Rheumatoid Arthritis","enrollment":717},{"nctId":"NCT00870467","phase":"PHASE3","title":"A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":334},{"nctId":"NCT00305539","phase":"PHASE3","title":"HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2006-05","conditions":"Giant Cell Arteritis","enrollment":69},{"nctId":"NCT00420927","phase":"PHASE4","title":"Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-12","conditions":"Rheumatoid Arthritis","enrollment":1032},{"nctId":"NCT00477893","phase":"PHASE4","title":"Danish Multicenter Study of Adalimumab in Spondyloarthritis","status":"UNKNOWN","sponsor":"Glostrup University Hospital, Copenhagen","startDate":"2006-02","conditions":"Spondyloarthritis","enrollment":52},{"nctId":"NCT00445432","phase":"PHASE2, PHASE3","title":"A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-03","conditions":"Crohn's Disease","enrollment":82}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":97,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Humira SC","genericName":"Humira SC","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"Humira SC is a subcutaneous formulation of adalimumab, a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}